|
November 12, 2008
International Drug and Explosive Detection Firm IDenta Corp. Announces Five New Patent Applications
Company's R&D Developing New Products That Will Generate Significant New Revenues
JERUSALEM--(Marketwire - November 10, 2008) - IDenta Corp. (PINKSHEETS: IDTA) announced today that it is completing the submission of five new international patent applications for its drug precursor and explosive detection products. The new patents will add to the company's four existing patents for cocaine and crack detection, heroin detection, ecstasy detection and its patent for chemical detection product packaging.
"These new patents will add significant book value to the company's assets," asserted Yaacov Shoham, IDTA CEO. "Each new product addresses either a critical new need, such as drug precursors, or is an important refinement to existing drug detection products. There is great demand for each of these new IDenta products, and we believe that in the coming years they will add significant revenue and profits to our bottom line."
"IDenta's continued research and development team," Shoham continued, "is unique in this industry. Most companies have simply continued to package the same chemical detectors for many years without further investigation and refinement. They have a small or no R&D department. IDenta continues to not only make improvements because of our dedicated R&D team, but we are creating products that correct mistakes found in previously accepted chemistry, such as our new ephedrine detectors."
The new IDenta chemical detection patents will be for:
1. Gamma hydroxybutyrate -- GHB. This illicit drug is colorless and odorless and is often referred to as the "date rape drug."
2. Triacetone Triperoxide -- TATP. This is an explosive substance made from acetone, peroxide and other easily obtainable ingredients. TATP is extremely dangerous and is commonly used in terrorist attacks in the Middle East.
3. Ephedrine -- known primarily as one of the most dangerous of dietary supplements, this dangerous chemical is also a critical ingredient used in the production of methamphetamine. IDenta is applying for a patent for both drug detection and precursor detection.
4. Acetic anhydride is a clear, colorless liquid with a very pungent, penetrating, vinegar-like odor that combines with water to form acetic acid. The IDenta patent will be for this precursor chemical used in the production of heroin.
5. Marijuana fast blue BB -- IDenta is applying for a drug detector patent.
"Many of drug detection products on the market today are presumptive not precise," asserted IDTA CEO Yaacov Shoham. "That will never be the case with any IDenta product. Each product we patent and produce for sale will always be easy to use, provide instant results and yield no false positives. When IDenta drug, precursor and explosive detection products change colors you can be assured that you have positively identified the substance in question."
ABOUT IDENTA
Since 2003, IDenta Corporation has been recognized as a worldwide leader in the development of proprietary on-site drug, drug precursor and explosive detection kits. IDenta develops, manufactures and distributes products for the both professional and civil markets which consistently pass the highest qualifications and testing procedures of law enforcement and security agencies around the world.
Accutest® IDenta products are being promoted through major Law Enforcement trade journals, such as The Law Enforcement Technology Magazine, Law Officer Magazine, American Probation and Parole Journal, the NarcOfficer magazine and Police Magazine. Both companies and their representatives are also participating in numerous industry trade shows. Accutest® IDenta is also a nominee for the 2008 Forensics Innovation Awards by the Cygnus Law Enforcement Group.
Information concerning IDenta's entire product line may be found at www.IDenta.biz. and www.accutest.net.
DISCLAIMER
Certain of the statements contained herein may be, within the meaning of the federal securities laws, "forward-looking statements" that are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements are based on management's expectations as of the date hereof, and the company does not undertake any responsibility to update any of these statements in the future.
For Investor Relations, lobbying interests or information concerning IDenta's products internationally or the development of new chemical detectors, contact: Yaacov Shoham, IDenta Corp., CEO, Tel: +972-52-6554487, fpi@drugsdetector.com. www.identa.biz
For Investor Relations in the US, contact: Randy Jacobs, Corporate Spokesman, IDentaNews@sitcomllc.com, 1-800-316-9437.
For information about the Accutest® - IDenta products in the US, please contact: Mr. Eyal Golan, COO, JANT PHARMACAL CORPORATION, 16255 Ventura Blvd. #505, Encino, CA 91436, Toll Free: 800-676-5565, 661-478-0582 (mobile), golan@accutest.net, www.accutestidenta.net.
|
